Dahiroc, Rachel L.
HRN: 04-03-01 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/14/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
05/14/2025
05/20/2025
IV
2.25g
Q12
UTI, Pneumonia
Waiting Final Action
Indication: Empiric Type of Infection: Urinary TractPneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes